IL1B and flatulence: In our future studies to mitigate the effects of SLS-driven inflammatory signaling during subcutaneous GAS skin infection, we will seek to incorporate some of the recent advances pertaining to treatment dosage and delivery, particularly for our small molecule inhibitors, as well as examining alternative IL-1β blockade mechanisms.